Carlsmed Reports Strong Q1 2026 Gross Margin Increase and Advances in Commercialization of Multiple Spine Products

Economic Observer NetworkCarlsmed, Inc. Achieves Gross Margin Increase in Q1 2026, Breakthroughs in Commercialization and Clinical Research of Spine-Related Products, New Product Launches to Follow.

Performance Operation Status:

Gross margin increased to 77.1%, but operating expenses significantly rose, primarily due to increased investments in R&D, sales, and marketing.As of March 31, 2026, the company's total cash and equivalents amounted to $97.1 million.。

Business Progress:

The first quarter of 2026 marks the first full commercial sales quarter for the aprevo cervical product. In February 2026, the company completed the first surgery using the corra™ personalized cervical plate system and also completed the first surgery utilizing the aprevo bilateral posterior approach technology, expanding the application of its personalized lumbar platform.The company is expected to launch the corra™ patient-specific fixation product portfolio in late 2026.。

Product Development Progress:

Carlsmed, Inc. published peer-reviewed data from a retrospective cohort study in the *Global Spine Journal*, showing that its aprevo personalized lumbar implants reduced patient reoperation rates by 74% compared to traditional implants.。

The above content is based on publicly available information and does not constitute investment advice.